HC Wainwright Reaffirms Buy Rating for TransCode Therapeutics (NASDAQ:RNAZ)

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $3.00 price objective on the stock.

TransCode Therapeutics Stock Down 4.0 %

Shares of RNAZ stock opened at $0.35 on Friday. The stock has a 50-day simple moving average of $0.49 and a 200 day simple moving average of $0.69. TransCode Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $18.66.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). On average, equities research analysts anticipate that TransCode Therapeutics will post -2.06 EPS for the current year.

Hedge Funds Weigh In On TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management lifted its position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,138 shares of the company’s stock after acquiring an additional 30,000 shares during the period. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent quarter.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.